Drug intelligence / Profile preview

IMT-0124

Development stage: Preclinical
Lead developer: ImunoTera

Overview

IMT-0124 is an early-stage pharmaceutical candidate currently in preclinical development by the Brazilian biotechnology company ImunoTera. It is being investigated for the treatment of HIV/AIDS. As of early 2024, the specific modality (such as whether it is a recombinant protein, DNA vaccine, or monoclonal antibody) and the precise biological targets have not been publicly disclosed, with the company's pipeline listing these details as 'to be defined' (TBD). ImunoTera generally focuses on developing immunotherapies and therapeutic vaccines designed to prime the immune system against viral infections and cancer.

Beyond the preview

Go deeper on IMT-0124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMT-0124.

Explore the full profile